Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Multicenter, Open Label, Study of LEE011 in Combination With MEK162 in Adult Patients With NRAS Mutant Melanoma

NCT01781572 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01781572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01781572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Multicenter, Open Label, Study of LEE011 in Combination With MEK162 in Adult Patients With NRAS Mutant Melanoma
Lead sponsor
Pfizer
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2013
Completion date
February 20, 2018
Enrollment
102 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic nras mutant melanoma